{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:19:00Z","timestamp":1789993140016,"version":"4.0.1"},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,8,26]],"date-time":"2005-08-26T00:00:00Z","timestamp":1125014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2005,10]]},"abstract":"<jats:p><jats:bold>Background and Objectives\u2002<\/jats:bold> To reduce the risk of transfusion\u2010transmissible viruses entering the blood supply, the nucleic acid amplification testing (NAT) was implemented to screen Scottish and Northern Irish blood donations in minipools. After 5 years of NAT for hepatitis C virus (HCV) and 2 years for human immunodeficiency virus\u20101 (HIV\u20101), the yield of serologically negative, nucleic acid positive \u2018window donations\u2019 and cost\u2010benefit of NAT is under review.<\/jats:p><jats:p><jats:bold>Materials and Methods\u2002<\/jats:bold> When the Scottish National Blood Transfusion Service (SNBTS) implemented NAT in 1999, a fully automated \u2018black box\u2019 system was not available. Therefore, an \u2018in\u2010house\u2019 assimilated NAT assay was developed, validated and implemented. The system is flexible and allows testing for additional viral markers to be introduced with relative ease.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> The HCV and HIV NAT assays have 95% detection levels of 7\u00b725\u00a0IU\/ml and 39\u00b78\u00a0IU\/ml, respectively, as determined by probit analysis. One HCV (1 in <jats:bold>1\u00b79<\/jats:bold> million) and one HIV (1 in <jats:bold>0\u00b777<\/jats:bold> million) window donation have been detected in 5 and 2 years, respectively, of NAT.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> The SNBTS NAT assays are robust and have performed consistently over the last 5 years. The design of the in\u2010house system allowed HIV NAT to be added in 2003 at a relatively small additional cost per sample, although for both assays, the royalty fee far exceeds the cost of the test itself. Clearly NAT has a benefit in improving the safety of the blood supply although the risks of transfusion\u2010transmitted viral infections, as reported in the Serious Hazards of Transfusion (SHOT) report, are extremely low. Also, in UK the yield of HCV antibody negative, NAT positive donations is far lower than predicted although the early detection of an HIV window period donation and the increase of HIV in the blood donor and general populations may provide a stronger case for HIV NAT.<\/jats:p><jats:p><jats:bold>Summary sentence\u2002<\/jats:bold> The yield of HCV and HIV NAT in UK is significantly less than that anticipated from statistical models.<\/jats:p>","DOI":"10.1111\/j.1423-0410.2005.00686.x","type":"journal-article","created":{"date-parts":[[2005,8,26]],"date-time":"2005-08-26T08:29:25Z","timestamp":1125044965000},"page":"128-134","source":"Crossref","is-referenced-by-count":25,"title":["Detection of HCV and HIV\u20101 antibody negative infections in Scottish and Northern Ireland blood donations by nucleic acid amplification testing"],"prefix":"10.1111","volume":"89","author":[{"given":"L. M.","family":"Jarvis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. C.","family":"Dow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cleland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lycett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Petrik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,8,26]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2000.7810057.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3148.2002.00384.x"},{"key":"e_1_2_5_4_2","first-page":"54","article-title":"HIV\u2010positive blood donations: Changing times, new responses","volume":"13","author":"Franklin IM","year":"2005","journal-title":"Transfus Med"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.1999.7630170.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2001.00093.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2000.7840217.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-0934(02)00187-8"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-76-10-2493"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-73-5-1131"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0042-9007.2004.00387.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2005.00579.x"},{"key":"e_1_2_5_13_2","unstructured":"European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products: The introduction of nucleic acid amplification technology (NAT) for the detection of hepatitis c virus RNA in plasma pools (CPMP\/BWP\/390\/97) March 24 1998 London. Available at:http:\/\/www.emea.eu.int\/pdfs\/human\/bwp\/026995en.pdf(accessed 26 July 2005)"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199606273342601"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3148.1998.00130.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2003.00296.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040085"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0042-9007.2004.00416.x"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)04719-4"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.330.7483.104"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08663-4"},{"key":"e_1_2_5_22_2","first-page":"21","article-title":"Surveillance of blood\u2010borne infections in donated blood, Scotland 2003","volume":"39","author":"Dow BC","year":"2005","journal-title":"HPS Weekly Report"},{"key":"e_1_2_5_23_2","first-page":"10","article-title":"HIV and other Sexually Transmitted Infections in the United Kingdom in 2003. The HIV epidemic in the United Kingdom","author":"The UK Collaborative Group for HIV and STI Surveillance: Focus on Prevention","year":"2004","journal-title":"Health Protection Agency Centre for Infections"},{"key":"e_1_2_5_24_2","unstructured":"Health Protection Scotland: Focus: HIV in Scotland Review 2004.HPS Weekly Report2005; 39:2005\/03:18\u201319. Available at:http:\/\/www.show.scot.nhs.uk\/scieh\/PDF\/pdf2005\/0503.pdf(accessed 26 July 2005)"},{"key":"e_1_2_5_25_2","unstructured":"Serious Hazards of Transfusion (SHOT) Steering Group: Summary of Annual Report 2003 2004. Manchester SHOT Office. Available at:http:\/\/www.shotuk.org(accessed 26 July 2005)"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1423-0410.2005.00686.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1423-0410.2005.00686.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T06:28:03Z","timestamp":1697264883000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1423-0410.2005.00686.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,26]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["10.1111\/j.1423-0410.2005.00686.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1423-0410.2005.00686.x","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,26]]}}}